Publication:
The response to hepatitis B vaccine: does it differ in celiac disease?

dc.contributor.authorsErtem, Deniz; Gonen, Ismail; Tanidir, Cansaran; Ugras, Meltem; Yildiz, Aysegul; Pehlivanoglu, Ender; Eksioglu-Demiralp, Emel
dc.date.accessioned2022-03-12T17:48:31Z
dc.date.accessioned2026-01-11T08:51:55Z
dc.date.available2022-03-12T17:48:31Z
dc.date.issued2010
dc.description.abstractObjectives There is a relationship between nonresponsiveness to hepatitis B virus (HBV) vaccine and certain human leukocyte antigen (HLA) genotypes. In healthy population, 4-10% vaccine recipients fail to produce protective levels of antibodies to the HBV vaccine after standard immunization depending upon age and the presence of various underlying diseases. Celiac disease (CD) is an HLA-associated immunological disease. It has been suggested that certain HLA haplotypes which are linked to CD are associated with nonresponse to HBV vaccine as well. The aim of this study is to assess the response to HBV vaccine prospectively in a group of CD and to explore the potential link between CD and HBV vaccine nonresponse by studying shared HLA haplotypes. Patients and methods Sixty-three previously diagnosed celiac patients who were on a strict gluten-free diet (GFD) and 54 healthy children were evaluated serologically for anti-HBs status. Celiac children who were anti-HBs negative at baseline were fully vaccinated prospectively, and reevaluated for the response to HBV vaccine. To estimate the role of HLA type in HBV vaccine response in celiac patients, a subgroup of both patients and control participants had HLA genotypes performed. Results At enrollment, 27 (67.5%) children with CD and 48 (85.2%) healthy children were anti-HBs positive, and the difference between patients and controls was statistically significant (P < 0.05). However, failure to respond to HBV vaccine was only 3.6% (response rate 96.4%) in prospectively vaccinated celiac patients. There was no relationship between HLA type and vaccine nonresponse in our study group. Conclusion The response to HBV vaccine in celiac children who were compliant to GFD is not different from a healthy population. CD may be one of the immune diseases associated with a high rate of HBV vaccine nonresponse but it might not be permanent and treatment with GFD and compliance to the treatment may ameliorate the immune response to HBV vaccine in celiac children. Eur J Gastroenterol Hepatol 22:787-793 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
dc.identifier.doi10.1097/MEG.0b013e32832e9d41
dc.identifier.eissn1473-5687
dc.identifier.issn0954-691X
dc.identifier.pubmed19584738
dc.identifier.urihttps://hdl.handle.net/11424/229969
dc.identifier.wosWOS:000278569900003
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofEUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectceliac disease
dc.subjectchildren
dc.subjecthepatitis B
dc.subjecthuman leukocyte antigen type
dc.subjectvaccine response
dc.subjectLONG-TERM IMMUNOGENICITY
dc.subjectVIRUS
dc.subjectHLA
dc.subjectNONRESPONSE
dc.subjectEFFICACY
dc.subjectRESPONSIVENESS
dc.subjectPROTECTION
dc.subjectANTIGEN
dc.subjectBINDING
dc.subjectTRIAL
dc.titleThe response to hepatitis B vaccine: does it differ in celiac disease?
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage793
oaire.citation.issue7
oaire.citation.startPage787
oaire.citation.titleEUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
oaire.citation.volume22

Files